Regulatory Compliance of Health Claims on Omega-3 Fatty Acid Food Supplements

被引:1
|
作者
Fuentes, Jelena Banovic [1 ]
Beara, Ivana [2 ]
Torovic, Ljilja [1 ,3 ]
机构
[1] Univ Novi Sad, Fac Med, Dept Pharm, Novi Sad 21000, Serbia
[2] Univ Novi Sad, Fac Sci, Dept Chem Biochem & Environm Protect, Novi Sad 21000, Serbia
[3] Univ Novi Sad, Fac Med, Ctr Med & Pharmaceut Invest & Qual Control, Novi Sad 21000, Serbia
关键词
consumer information; food labelling; public health; supplementation; EICOSAPENTAENOIC ACID; DIETARY; FOCUS; RISK; N-3;
D O I
10.3390/foods14010067
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Unlike the mandatory information that must be provided on a food supplement label, health claims are voluntary. This study assesses the regulatory compliance of omega-3 fatty acid (omega-3-FA) supplement label claims. Of the 97 supplements, 76 (78.4%) carried verbal claims referring to active substance, of which 68 (89.5%) were claims specific to omega-3-FA. According to the European Union Health Claims Registry, 107 claims listed on 59 supplements were authorized, as opposed to nine unauthorized claims on nine supplements. The degree to which claims aligned with regulatory standards, expressed in terms of scores scaled from 0 to 1, was the highest for supplements intended for pregnant women (1), while, in the case of adults, the mean score was 0.76 +/- 0.35, and, in case of children, was 0.85 +/- 0.27. Statistical analysis revealed a minor tendency for higher health claim scores to be associated with lower product prices. Furthermore, differences in compliance levels across groups of supplements formed according to the country of origin/sources of omega-3-FA/target populations were explored. The main differences were associated with products from Sweden and Italy/fish oil/supplements for pregnant women. A comparison of the daily intake of omega-3-FA provided by the supplement (based on labeled information) with the intake requirements for supplements with claims referring to omega-3-FA, supported 91 claims, five were unsubstantiated, and 11 were missing required data. Supplements also contained mineral- (19 approved) and vitamin-related claims (73, of which 9 were unauthorized). This study's findings reveal the extent of misuse of labelled information in markets that require pre-market supplement registration. Importantly, the non-compliance of health claims can significantly undermine consumer trust.
引用
收藏
页数:35
相关论文
共 50 条
  • [31] A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
    Watson, Henry
    Mitra, Suparna
    Croden, Fiona C.
    Taylor, Morag
    Wood, Henry M.
    Perry, Sarah L.
    Spencer, Jade A.
    Quirke, Phil
    Toogood, Giles J.
    Lawton, Clare L.
    Dye, Louise
    Loadman, Paul M.
    Hull, Mark A.
    GUT, 2018, 67 (11) : 1974 - 1983
  • [32] Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
    Jonathan Fialkow
    American Journal of Cardiovascular Drugs, 2016, 16 : 229 - 239
  • [33] Omega-3 polyunsaturated fatty acid supplements and cognitive decline: Singapore longitudinal aging studies
    Q. Gao
    M. Niti
    L. Feng
    K. B. Yap
    Tze Pin Ng
    The journal of nutrition, health & aging, 2011, 15 : 32 - 35
  • [34] Omega-3 fatty acid supplements and recurrent miscarriage: A perspective on potential mechanisms and clinical evidence
    Mu, Fangxiang
    Huo, Huyan
    Wang, Mei
    Wang, Fang
    FOOD SCIENCE & NUTRITION, 2023, 11 (08): : 4460 - 4471
  • [35] Vitamin D and Marine Omega-3 Fatty Acid Supplements and Prevention of Heart Failure Hospitalization
    Djousse, Luc
    Cook, Nancy R.
    Kim, Eunjung
    Bubes, Vadim
    Lee, I-Min
    Joseph, Jacob
    Albert, Christine M.
    Buring, Julie E.
    Gaziano, John M.
    Manson, Joann E.
    CIRCULATION, 2019, 140 (25) : E998 - E998
  • [36] Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
    Fialkow, Jonathan
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (04) : 229 - 239
  • [37] The omega-3 fatty acid peroxidation paradox
    Budowski, P
    REDOX REPORT, 1996, 2 (01) : 75 - 77
  • [38] Clarifying omega-3 fatty acid recommendations
    Biro, Andy
    CANADIAN FAMILY PHYSICIAN, 2006, 52 : 1060 - 1061
  • [39] OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENTS AND COGNITIVE DECLINE: SINGAPORE LONGITUDINAL AGING STUDIES
    Gao, Q.
    Niti, M.
    Feng, L.
    Yap, K. B.
    Ng, T. -P.
    JOURNAL OF NUTRITION HEALTH & AGING, 2011, 15 (01): : 32 - 35
  • [40] HIGH-DOSE OMEGA-3 FATTY ACID SUPPLEMENTS REDUCE HYPERLIPIDEMIA IN TRANSPLANT RECIPIENTS
    Filler, Guido
    Casier, Shelley
    Sharma, Ajay P.
    Grimmer, Joanne
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 115 - 115